A critical review on oligometastatic disease: a radiation oncologist's perspective

Abstract

Since the first definition by Hellman and Weichselbaum in 1995, the concept of OligoMetastatic Disease (OMD) is a growing oncology field. It was hypothesized that OMD is a clinical temporal window between localized primary tumor and widespread metastases deserving of potentially curative treatment. In real-world clinical practice, OMD is a "spectrum of disease" that includes a highly heterogeneous population of patients with different prognosis. Metastasis directed therapy with local ablative treatment have proved to be a valid alternative to surgical approach. Stereotactic body radiation therapy demonstrated high local control rate and increased survival outcomes in this setting with a low rate of toxicity. However, there is a lack of consensus regarding many clinical, therapeutic, and prognostic aspects of this disease entity. In this review, we try to summarize the major critical features that could drive radiation oncologists toward a better selection of patients, treatments, and study endpoints. With the help of a set of practical questions, we aim to integrate the literature discussion.

Keywords: Oligometastasis; Oligometastatic disease; Prognostic factors; Stereotactic body radiation therapy.

Fig. 1

Novel endpoints for OMD. ALT Ablative Local Treatment-adjusted Disease-Free Survival, WSPFS widespread Progression-Free Survival, TNT or NEST Time to New Systemic treatment